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Abstract 
 
Gao, Yuefeng (M.S., Department of Chemistry and Biochemistry) 
Biochemical Characterization of the Human Mediator Complex 
Thesis directed by Dr. Dylan J. Taatjes 
 
           Accurate regulation of transcription is essential for normal gene expression and proper 
organism development. Defects in regulatory components are often related to serious human 
diseases, and even lethality. The multi-subunit human Mediator complex is required for 
transcription and regulation of all protein-coding genes. Mediator regulates transcription by 
mediating signals between activators or repressors and the general transcription machinery. 
However, most of the molecular mechanisms regarding the Mediator complex remain unclear. 
           The composition of the Mediator complex can vary and Mediator complexes of 
different subunit composition can be isolated using different purification procedures. The 
Mediator complexes usually exist in two forms: larger complexes such as CDK8-Mediator 
and T/G-Mediator (2.0 MDa) and smaller complexes such as core Mediator (1.2 MDa). These 
two forms of Mediator complexes regulate transcription positively or negatively. The CDK8-
Mediator complex and the T/G-Mediator complex have been shown to have kinase and/or 
acetyltransferase activities, but whether additional enzyme activities are present is far from 
clear. During my thesis work I studied assorted enzymatic activities of T/G-Mediator by 
various approaches. The results indicate that the Mediator complexes may possess additional 
enzymatic activities, such as methyltransferase and ubiquitin ligase function. Here, we 
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demonstrate that T/G-Mediator can methylate histone H3 and also that some Mediator 
subunit(s) are associated with the ubiquitination pathway.  
           RNA polymerase II coordinates with a wide range of factors and catalyzes DNA 
transcription to synthesize mRNA. One critical step of transcription initiation is the 
interaction between the Mediator complex and the carboxy-terminal domain (CTD) of the 
largest subunit of human RNA polymerase II that consists of 52 repeats of the general 
consensus sequence YSPTSPS. This Mediator-Pol II CTD interaction is believed to be 
important in transcriptional regulation, RNA processing and chromatin remodeling. Therefore, 
elucidating the mechanism of this interaction is crucial for understanding gene expression and 
developing potential clinical applications. Our lab used a chemical crosslinking method in 
order to identify which Mediator subunit(s) interact with CTD. The results indicated that there 
might be two or three Mediator subunits bound to the Pol II CTD. Western blot experiments 
using antibodies specific for Mediator subunits revealed that Med1 and Med23 likely interact 
with CTD. In addition, in vitro binding assays show that Med1 binds to the first half of CTD 
(repeats 1-24), but not to the second half (repeats 25-52). The molecular details of the 
interaction need to be explored using mass spectrometry along with combined approaches of 
molecular biology and biochemistry. 
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Chapter 1 
Introduction 
           Proper regulations of transcription and other nuclear events are required for 
mammalian cell growth, development and survival. Transcription in Eukaryotic cells is a 
complex biological process that requires numerous factors, including RNA polymerase II, 
general transcription factors (TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH), chromatin 
remodeling factors, gene-specific transcriptional regulators (activators and repressors), and 
Mediator (Lewis and Reinberg, 2003; Myers and Kornberg, 2000; Rachez and Freedman, 
2001). The Mediator complex is a vital regulatory complex that bridges signals between 
transcription factors and the general transcription machinery. Detailed study of the Mediator 
complex will significantly help us understand gene expression and related human diseases. 
  
1.1 Mediator  
           Mediator is a large multi-subunit complex and was first discovered from yeast (Kim et 
al., 1994; Thompson et al., 1993). Mediator is required for transcription in vivo and regulates 
activator-dependent transcription in vitro (Knuesel et al., 2009; Meyer et al., 2010; Takagi 
and Kornberg, 2006). Functionally distinct Mediator complexes with different subunit 
composition can be specifically purified (Bourbon et al., 2004; Conaway et al., 2005; Myers 
and Kornberg, 2000; Taatjes, 2010). The mammalian Mediator complexes purified in 
different research groups have diverse yet overlapping subunit compositions (Table 1.1) 
(Conaway et al., 2005; Jiang et al., 1998, Meyer et al., 2008), and interestingly no known 
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enzyme activity is associated with Mediator except for acetylation and phosphorylation by 
T/G-Mediator and CDK8-Mediator (Knuesel et al., 2009; Meyer et al., 2008; Taatjes, 2010). 
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Table 1.1 Comparison of mammalian Mediator-like complexes. Mediator subunits 
identified in different purifications are indicated with blue; Mediator subunits unidentified are 
indicated with yellow. Subunits are classified as the head, middle, tail, or unassigned modules 
(Conaway et al., 2005). Mammalian Mediator complexes and subunit compositions are listed 
on the left of the table. The subunit compositions of Mediator complexes from HeLa or 293 
cells are identified by immunoaffinity chromatography and MudPIT on the right of the table 
(Boube et al., 2002; Conaway et al., 2005; Sato et al., 2004). 
        
             Mediator is essential for expression of protein-coding genes, and plays an important 
role in activation and repression of eukaryotic transcription. The exact mechanism by which 
Mediator regulates transcription has not been completely understood. In summary, Mediator 
serves as a regulatory target to activate transcription by direct interaction with DNA binding 
transcription factors. Furthermore, substantial evidence reveals that Mediator also can 
stimulate basal transcription (Baek et al., 2002; Mittler et al., 2001; Taatjes, 2010). Some 
biochemical studies partially depict many interactions between different activators and 
Mediator subunits, and also demonstrate how critical some Mediator subunits are in cell 
development (Table 1.2) (Lewis and Reinberg, 2003).  
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Table 1.2 Human Mediator complex. Listed in the columns are subunits of human Mediator 
complex (left),  activators interacting with diverse subunits (middle), and defects of the 
subunit mutations (right) (Lewis and Reinberg, 2003).  
 
1.2 RNA polymerase II Rpb1 CTD structure and function 
           RNA polymerase II (Pol II) is an essential enzyme for transcription of protein-coding 
genes in eukaryotic cells. The carboxy-terminal domain (CTD) of the largest subunit Rpb1 of 
RNA Polymerase II consists of repeating seven amino acid motif Y1S2P3T4S5P6S7. The 
number of heptapeptide repeats varies depending on the genome complexity. Drosophila 
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CTD has 43 repeats, yeast CTD has 26 repeats, and human CTD has 52 repeats (Figure 1.1) 
(Palancade and Bensaude, 2003).  
 
 
Figure 1.1 The human RNA Pol II CTD sequence (Palancade and Bensaude, 2003). 
 
The Pol II CTD is an inherently unstructured tail-like extension but is highly conserved from 
yeast to mammals during evolution (Phatnani and Greenleaf, 2006), suggesting its 
fundamental importance in transcription and regulation. The Pol II CTD is essential for 
organization of transcription, pre-mRNA processing and chromatin remodeling (Gerber et al., 
1995; Hirose and Manley, 2000; Hirose and Ohkuma, 2007; Howe, 2002; Misteli, 2000; 
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Proudfoot et al., 2002). The partial loss of the CTD repeats causes cell damage, even lethality 
(Meinhart et al., 2005; Phatnani and Greenleaf, 2006).  
          The free Pol II CTD structure is highly flexible. NMR studies proposed that the CTD 
has a population of β-turns at SPXX motifs in the CTD repeats (Meinhart et al., 2005). The 
CTD serves as a flexible platform to coordinate various nuclear factors for proper regulation 
of gene expression (Meinhart et al., 2005; Phatnani and Greenleaf, 2006). Indeed, a Pol II 
CTD repeat has five potential phosphorylation sites (Y1, S2, T4, S5, S7); however, CTD 
phosphorylation occurs mainly at S2 and S5, which is specifically recognized by different 
associated factors (Meinhart et al., 2005). The distribution of Pol II CTD phosphorylation 
plays a major role in transcription and regulation in vivo. The dynamic changes in serine 
phosphorylation of the CTD, referred to as the “CTD code” in regulation of gene expression, 
are implicated in integrating multiple nuclear events (Figure 1.2) (Phatnani and Greenleaf, 
2006). 
 
 
Figure 1.2 RNA Pol II CTD phosphorylation patterns with associated factors (Phatnani 
and Greenleaf, 2006). 
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Various kinases have been reported to phosphorylate the CTD (Brès et al., 2008; Govind et 
al., 2010; Knuesel, et al., 2009; Rother and Strasser, 2007), such as CDK7, CDK8 and CDK9. 
Under the control of site-specific CTD kinases and phosphatases, the phosphorylation pattern 
changes during the transcription cycle, which leads to recruitment of specific transcription 
factors (Phatnani and Greenleaf, 2006). Biochemical studies revealed that CTD 
phosphorylation at S2 and S5 is functionally different; however, the specificity of CTD 
phosphorylation remains elusive. Mass spectrometry might be the best tool for the 
determination of the exact CTD phosphorylation pattern (Geromanos et al., 2000; Han et al., 
2006; Hansen and Pergantic, 2006; Haydon et al., 2003). 
 
1.3 RNA Pol II CTD-Mediator interaction  
           The human Mediator complex is a large multi-protein coactivator that supports 
transcriptional activation. Mediator serves as a regulatory target of a number of transcriptional 
factors and interacts with RNA polymerase II, forming a tight and functional complex with 
distinct conformational states (Lewis and Reinberg, 2003; Myers and Kornberg, 2000; Näär et 
al., 2002; Taatjes et al., 2004). Mediator usually regulates transcription by bridging signals 
between transcriptional factors and basal transcriptional machinery. Reversible associations of 
different nuclear factors with Mediator strongly affect how Mediator regulates transcription 
(Figure 1.3) (Taatjes, 2010). Significantly, Mediator undergoes a distinct conformational shift 
when bound to specific nuclear factors, which plays a key role in recruitment mechanisms 
(Meyer et al., 2010; Taatjes et al., 2002). 
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Figure 1.3 Mediator regulates transcription (Taatjes, 2010). 
 
           A critical step of transcription initiation is the interaction between Mediator and the 
unphosphorylated Pol II CTD. The CTD-Mediator interaction is essential for Mediator 
functions in transcriptional regulation (Meinhart et al., 2005). In the absence of the CTD 
repeats, Mediator cannot stimulate transcription. In fact, transcription will not occur 
without the Pol II CTD. Studies from electron microscopy along with 3D reconstruction 
revealed that Mediator usually consists of three distinct domains, termed head, middle 
and tail (Dotson et al., 2000). The Pol II CTD may bind between the head and middle 
domains (Kang et al., 2001; Meinhart et al., 2005). To date, it is believed that Mediator 
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strongly binds the unphosphorylated CTD, and CTD phosphorylation dissociates this 
interaction (Max et al., 2007). However, the Mediator subunit(s) that interacts with the Pol II 
CTD remains unknown. Identification of CTD-interacting subunit(s) will greatly help 
elucidate relevant mechanisms of the CTD-Mediator interaction, and furthermore better 
understand how the CTD functions in transcription. 
 
1.4 Enzymatic activities of Mediator 
           A protein is often chemically modified by various enzymes after translation, called 
post-translational modification, which is an important step in biological regulation.  The 
posttranslational modifications of amino acids greatly extend the diversity of protein functions 
by covalently attaching chemical functional groups, such as phosphate, acetate, or a methyl 
group. The posttranslational modifications can change the properties of the protein, and often 
correlate with structural changes. Enzymes attach these covalent modifications, which can be 
classified into different types, such as phosphorylation, methylation, ubiquitination and 
acetylation. These chemical modifications are reversible by the action of a modifying enzyme 
that possesses the opposite role.  
           Subunits of the core Mediator complex possess no identifiable functional motifs for 
enzymatic activities according to bioinformatics studies (Taatjes, 2010). However, it was 
surprising that there are little known enzymatic activities in Mediator subunits, because 
Mediator has important functions in cells, such as serving as a target site recognized by 
nuclear factors and facilitating assembly and disassembly of the cellular complexes (Ebmeier 
and Taatjes, 2010; Meyer, et al., 2010; Myers, et al., 1999; Tóth-Petróczy, et al., 2008). 
Recently, substantial evidence has revealed that large Mediator complexes function as 
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enzymes, and some Mediator subunits are involved in protein modifications in biological 
pathways (Akoulitchev et al., 2000; Brower, et al., 2002; Knuesel, et al., 2009; Meyer, et al., 
2008). It is possible that some subunits of this large and highly conserved protein complex 
Mediator may possess enzymatic activities. 
 
1.5 Histone modification 
           Histone proteins are highly basic and were discovered in eukaryotic cell nuclei, 
packaging the DNA into chromatin with around 10,000 fold DNA compacting. The core 
histones (H2A, H2B, H3 and H4) are structurally similar and highly conserved in evolution. 
Histones are essential in gene regulation (Grant, 2001; Luger et al., 1997; Wu and Grunstein, 
2000).  
           It is well known that post-transcriptional modifications of histones play a significant 
role in nuclear events, which facilitates biological process such as DNA repair, replication and 
transcription (Brian et al., 2000; Grant, 2001; Singh et al., 2010).  An unstructured amino-
terminal tail of the core histone provides many sites for a variety of posttranslational 
modifications, including acetylation, phosphorylation, methylation and ubiquitination (Figure 
1.4) (Higashi et al., 2010; Kouzarides, 2007; Meyer et al., 2008). 
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Figure1.4 Histone-modifying enzymes (Kouzarides, 2007). 
 
           Clearly the histone modifications demonstrate the interactions between histones and 
DNA or other nuclear factors, which regulates chromatin structure. Identification of the 
multitude of histone modifications and enzymes generating them fundamentally help us to 
understand replication and transcription. 
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1.6 Statement of Purpose 
            The first purpose of this thesis is to uncover RNA Pol II CTD-bound Mediator 
subunits, and further determine the interaction mechanism. Apparently Pol II CTD-Mediator 
plays a key role in transcription regulation, however, little is known about the interaction 
details. Here, a chemical crosslinking method is employed to determine which Mediator 
subunit can bind the Pol II CTD. The bait protein Pol II CTD must have a free sulfhydryl 
group and react with the crosslinking reagent, therefore, several cysteine mutants of Pol II 
CTD were made in different positions of the repeats. After crosslinking, Pol II CTD-
interacting Mediator subunits were disassociated by DTT and urea treatments, and identified 
by Western blot and mass spectrometry. Elucidating the mechanism of the Pol II CTD-
Mediator interaction will provide important insight into how transcription is specifically 
regulated. 
           The second purpose of this thesis was to study potential new enzymatic activities of the 
Mediator complexes. Protein sequence analysis of the core Mediator subunits indicates that 
there are no known enzymatic domains. But it is possible that the Mediator complexes harbor 
enzymatic activities that cannot be predicted based upon polypeptide sequence alone.  T/G-
Mediator purified from HeLa nuclear exacts is utilized to characterize potential Mediator 
enzymatic activities, such as phosphorylation, methylation and ubiquitination. Pol II CTD and 
histone proteins are essential in transcription, and these proteins are employed as the 
substrates modified by the Mediator complex. The major goal of the second project is to 
identify whether the purified Mediator complex possesses enzymatic activities, and which 
subunit catalyzes the modification, and what’s the modification profile.  Discovering potential 
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enzymatic activities of the Mediator complexes will significantly help us to better understand 
the scope of Mediator’s functions in transcription and regulation. 
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Chapter 2 
Materials and Methods 
 
2.1 Expression and purification of various recombinant proteins from bacteria 
           Human RNA Pol II CTD (repeats 1-52) and its deletion and cysteine mutants were 
subcloned into the Glutathione S-transferase gene fusion vector pGEX-4T-1 (Figure 2.1) (GE 
healthcare). We got all CTD constructs from the Tjian lab at the University of California at 
Berkeley. All CTD plasmids were transformed into BL21 cells. Individual fresh colonies were 
picked from LB agar plates containing antibiotics, and grown overnight for around 16 hours 
in the 37 °C shaker. Each 5ml overnight culture was added to one liter of fresh LB media 
contain 100 mg/ml ampicillin. Flasks were shaken at 37 °C until the (OD)600 reached 0.6 to 
0.8. Then 0.5 mM isopropyl-β-D-thiogalactopyranoside (IPTG) was added into the flask, and 
induced gene expression for 6 to 8 hours at 30 °C. For other proteins such as GST-SREBP, 
IPTG-induction time was 3 to 4 hours. Cells were harvested at 5,000 RPM for 15 minutes at 
4 °C. The supernatants were removed and the cell pellets were placed at -80 °C freezer after 
washing using 1x PBS with protease inhibitors. 
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Figure 2.1 Map of the Glutathione S-transferase gene fusion vector pGEX-4T-1 (GE 
healthcare). 
 
           The frozen cell pellets were thawed and resuspended in 0.15M HEGN buffer (50mM 
HEPES pH7.6, 0.15M KCl, 0.1mM EDTA, 10% glycerol, 0.02% NP-40) with protease 
inhibitors (1mM DTT, 1 mM Benzamidine, 0.25 mM PMSF, 1 mM Sodium Metabisultate, 1x 
Aprotinin) on ice. The cells were lysed by sonication. Lysates were cleared through 
centrifugation at 40,000 RPM for 30 minutes at 4ºC. The supernatants were incubated with 
pre-equilibrated glutathione sepharose 4B beads (GE healthcare) for an hour at 4 °C. The 
beads were washed five times with high salt buffer (50mM Tris-HCl pH7.9, 1M NaCl, 8mM 
CHAPS, 0.5mM EDTA, 10% glycerol, 0.5% NP-40), and then washed twice with 0.15M 
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HEGN. Finally, GST tagged CTD proteins were eluted using elution buffer (20 mM Tris, 0.1 
mM EDTA, 10% glycerol, 0.15M KCl) containing fresh 30mM GSH. The purified CTD 
proteins were dialyzed in 0.15M HEGN buffer at 4 °C, and snap frozen and stored in small 
aliquots at -80 °C freezer.  
 
2.2 Purification of Mediator from HeLa cells 
           Different Mediator complexes with distinct subunit composition are purified and 
characterized according to various preparation procedures. Both the core and T/G-mediator 
complexes were purified from HeLa cells (Figure 2.2). HeLa nuclear exacts were loaded into 
a pre-equilibrated P11 phosphocellulose column (Whatman).  0.5 M HEGN (20 mM HEPES 
pH 7.9, 0.1 mM EDTA, 10% glycerol, 0.1% NP-40, 0.5 M KCl) and 1 M HEGN (20 mM 
HEPES pH 7.9, 0.1 mM EDTA, 10% glycerol, 0.1% NP-40, 1 M KCl)  elutes (P0.5M and 
P1M) were dialyzed against 0.15 M HEGN to decrease the salt content. P0.5M flow-through 
fractions through HiTrap Q column were incubated with GST-SREBP bound GSH resins after 
ammonium sulfate precipitation, and finally the T/G-Mediator complexes were obtained after 
the GSH elutes were run on a linear 15%-40% glycerol gradient at 55,000K RPM for 6h at 
4ºC. P1M were loading into Poros Q column, and 1M HEMG (20 mM HEPES pH 7.9, 0.1 
mM EDTA, 10% glycerol, 2mM MgCl2, 1 M KCl) elutes (Q1M) were incubated with GST-
SREBP bound GSH resins. After pull-down assays, the core Mediator complexes were 
obtained from 15%-40% glycerol gradient fractions of the GSH elutes after 55,000 RPM 
spinning for six hour at 4ºC. Both gradient fractions were collected from the top of 
ultracentrifuge tubes in 100 μl aliquots. Both Mediator complexes’ profiles were examined 
by silver stained gel. 
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HeLa nuclear extract in buffer D
Cellulose phosphate, equilibrated in 0.1M HEMG
Flowthrough (0.1M)    0.3M               0.5M                1M HEMG
Dialysis in 0.15M HEGN Dialysis in 0.2M HEGN
HiTrap Q                          Poros Q
Flowthrough (0.15M)  0.3M  0.5M 1M    Flowthrough (0.2M)  0.4M   1M HEMG
Affinity purification using GST-SREBP
Glycerol gradient: 15% --40%
T/G-Mediator Core Mediator
(~2 MDa) (~1.2 MDa)
Dialysis in 0.15M HEMGAmmonium sulfate precipitation
 
Figure 2.2 Purification schemes of the endogenous core and T/G-Mediator  
 
2.3 Identification of Pol II CTD-interacting Mediator subunits using chemical 
crosslinking              
           Identification of protein-protein interactions is critical for understanding the dynamics 
of cellular signaling. Chemical crosslinking is a powerful and effective method to study the 
interactions. Generally, chemical crosslinkers can work for both transient and stable protein-
protein interactions. There are many chemical crosslinking reagents commercially available. 
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           The Mts-Atf-Biotin label transfer reagent from Pierce was utilized to study RNA Pol II 
CTD-Mediator interaction. This reagent has three functional groups: biotin group that can 
transfer to the unknown interacting protein for affinity detection and purification, 
methanethiosulfonate (Mts) group that is sulfhydryl-reactive and can label the bait protein in 
the reduced cysteine residue, and tetrafluorophenyl azide reactive group that is activated by 
UV light and can nonspecifically attach to the side chain and backbone of the interacting 
protein (Figure 2.3).  
 
 
Figure 2.3 Mts-Atf-Biotin (2-[N2-(4-azido-2,3,5,6-tetrafluorobenzoyl)-N6-(6-
biotinamidocaproyl)-L-lysinyl] ethyl methanethiosulfonate) (Pierce). 
 
           Here, for crosslinking experiments, the bait protein is the CTD cysteine mutants, and 
the prey protein is the unknown subunits of the Mediator complex. The crosslinking 
experiments were carried out according to the following procedure modified from the 
manufacturer’s instructions (Figure 2.4): prepared the GSH resins containing distinct CTD 
cysteine mutants according to the procedure 2.1, and incubated the GST-CTD cysteine mutant 
bound GSH resins in 1x PBS (0.1 M phosphate, 0.15 M NaCl; pH 7.2 ); dissolved 1-2 mg 
Mts-Atf-Biotin reagent in 25-50 µl of dimethyl sulfoxide (DMSO), and added the reagent into 
the tube to achieve around five fold molar excess over the CTD cysteine mutants, and gently 
mixed and incubated for 4 hours at 4°C; removed free crosslinking reagent by washing with 
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1x PBS;  thrombin digested to release labeled CTD cysteine mutants from the GST tag, and 
used NeutrAvidin beads to capture the biotin-labeled bait protein, and washed the beads with 
1x PBS; added the Mediator complexes (Dialyzed P1M elutes) into the biotin-labeled bait 
protein tube, and rocked the mixture for 4 hours in cold room, and washed with 0.5M PBS 
(0.1 M phosphate, 0.5 M NaCl; pH 7.2 ); photoactivated the Atf moiety with a UV light at 
300-370 nm; reduced disulfide bond using 50 mM DTT and dissociated the Mediator complex 
using 3 M Urea; finally, loaded the biotin-modified interacting Mediator subunits on SDS-
PAGE gels, and detected by silver stain and Western blot. Most of the above steps were 
conducted in subdued light or in the dark at 4 °C. 
 
 
Figure 2.4 Chemical crosslinking and label-transfer scheme (Pierce). 
         
2.4 In vitro enzymatic activity assays (Kinase, methyltransferase, and ubiquitin ligase) 
by Mediator 
           In vitro modification assays are powerful tools to test protein’s enzymatic activities. 
These assays use highly purified components for distinct tests, which is easier to handle. In 
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this thesis, I tested three Mediator complexes’ enzymatic activities: phosphorylation on RNA 
Pol II CTD, methylation and ubiquitination on histone proteins. Detailed procedures are 
summarized in the following sections. 
 
 2.4.1 In vitro kinase assay by the core and T/G-Mediator 
           Kinase assay used 2.5 µCi of γ-32P ATP for 10µl reaction, together with the Mediator 
complex and substrate in kinase buffer (25mM Tris-HCl pH 8.0, 0.1mM ATP, 0.1M KCl, 
10mM MgCl2, 2mM DTT). Reaction usually incubated at 30°C for 30 minutes, and then 
quenched with SDS loading buffer and separated on SDS-PAGE gel. The dried gel was 
exposed on the storage phosphor screen (GE healthcare) and scanned with the Typhoon 9400 
(GE healthcare).  
 
2.4.2 In vitro methylation assay by the T/G-Mediator complex 
           The methylation assay used 0.12-0.16 µCi of 
14
C-SAM (Adenosyl-L-methionine, S-
[methyl-
14
C]) as the methyl donor in 25 µl of methyltransferase buffer (50mM Tris-HCl pH 
9.0, 5mM MgCl2, 4mM DTT), together with the Mediator complex and substrate histone 
proteins made by Dr. Meyer in the Taatjes Lab. Reaction was carried out for an hour at room 
temperature. Protein samples were separated by SDS-PAGE. Coomassie blue-stained gel was 
use to check the equal loading of the substrate. Then the dried gel was exposed on the storage 
phosphor screen (GE healthcare) and scanned with the Typhoon 9400 (GE healthcare).  
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2.4.3 In vitro ubiquitination assay by the T/G-Mediator complex 
           The ubiquitination assays were performed by incubating the Mediator complex with 
0.5 μM E1, 5 μM UbcH5a (E2), 5 μM ubiquitin (BostonBiochem), 100 μM methylated 
ubiquitin (BostonBiochem), 1 μM ubiquitin aldehyde (BostonBiochem) in reaction buffer 
(10 mM ATP, 20 mM HEPES pH 7.4, 10 mM MgOAc, 300 mM creatine phosphate, and 0.5 
mg/ml creatine phosphokinase). The reactions were incubated for 2 hr at 30°C, and quenched 
by SDS loading buffer, and analyzed by SDS-PAGE. The samples were detected by Western 
blot using the antibody against ubiquitin. If Biotin-labeled ubiquitin was used, Streptavidin-
HRP was employed to check the assay products. 
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Chapter 3 
Results and Discussion 
 
3.1 RNA Pol II CTD-Mediator interaction 
           Generally, the Pol II CTD is functionally conserved through evolution in eukaryotes, 
but the number of CTD repeats and the length of the CTD varies markedly across species. So 
far, the functional importance of the Pol II CTD remains poorly understood. There is an 
accumulation of evidence that the CTD-Mediator interaction is very dynamic and plays 
important roles in nuclear events. The Mediator complexes are strongly bound to the 
unphosphorylated CTD, and dissociate upon CTD phosphorylation (Max et al., 2007; 
Meinhart et al., 2005; Phatnani and Greenleaf, 2006). The CTD-Mediator interaction 
facilitates transcription initiation and also mediates signals between activators or repressors 
and the general transcriptional machinery.  
 
3.1.1 Preparation of GST tagged Pol II CTD first half, second half and full length 
           GST fused Pol II CTD first half (repeats 1-24), the second half of the CTD (repeats 25-
52) and full length Pol II CTD (repeats 1-52) were successfully expressed and purified from E. 
coli BL21 cells for the CTD-Mediator interaction assay.    
           Mammalian RNA Pol II CTD consists of 52 repeats of the consensus sequence 
YSPTSPS, which is difficult for subcloning and purification. Interestingly, repeats 25-52 are 
more diverse than repeats 1-24 (Figure 1.1). 
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 Figure 1.1 The human RNA Pol II CTD sequence (Palancade and Bensaude, 2003). Serine 
at position 7 is not conserved in the second half of Pol II CTD. Serines at position 2and 5are 
major phosphorylation sites indicated in red, and unconserved amino acids are indicated in 
blue. 
 
What does this imply? Perhaps the first half is functionally different from the second half. To 
test the interaction with Mediator complexes, I prepared three proteins: CTD full length 
(repeats 1-52), the first half (repeats 1-24) and the second half of the CTD (repeats 25-52) 
(Figure 3.1). 
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Figure 3.1 Purified Pol II CTD first half, second half, and full length by GST affinity 
chromatography. Lane 1:Precision plus protein dual color standards (Bio-Rad); lanes 
2,3,4,5,6: BSA; lanes 7,8,9:  GST-CTD (1-24); lanes 10,11,12: GST-CTD (25-52); lanes 
13,14,15: GST-CTD full length. 
 
3.1.2 Preparation of GST tagged Pol II CTD cysteine mutants 
          GST fused Pol II CTD cysteine mutants (CTDr24C, r31C, r38C, r52C) were 
successfully expressed and purified from BL21 cells for chemical crosslinking experiments.  
           The chemical crosslinking Mts-Atf-Biotin label transfer reagent (Pierce) was used to 
capture Pol II CTD-interacting Mediator subunits. This reagent requires the bait protein with a 
free sulfhydryl group reacted with the Mts moiety. The wild type CTD repeats don’t have any 
free sulfhydryl group, therefore, four cysteine mutants (CTDr24C, r31C, r38C, r52C) of the 
Pol II CTD were made in the seventh amino acid residue of the repeat 24, 31, 38, 52, 
respectively. These Pol II CTD cysteine mutants were provided by the Tjian Lab at the 
  15  14  13 12  11  10   9   8   7    6    5    4    3   2    1  
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University of California at Berkeley. The CTD cysteine mutants were expressed and purified 
for the bait protein of chemical crosslinking experiments (Figure 3.2).  
 
 
 
Figure 3.2 Purified Pol II CTD cysteine mutants by GST affinity chromatography. Lane 
1: Precision plus protein dual color standards (Bio-Rad); lanes 2 and 4: GST-CTDr24C; lanes 
3 and 5: GST-CTDr52C. 
 
3.1.3 Preparation of untagged Pol II CTD cysteine mutants by Thrombin digestion 
           Untagged Pol II CTD cysteine mutants were obtained directly by Thrombin digestion 
on protein bound GSH resins. To enhance efficiency of chemical crosslinking and reduce 
interference of the GST tag, the endoprotease Thrombin (Sigma-Aldrich) was utilized to 
remove the tag directly from GST-CTD cysteine mutants bound GSH resins (Figure 3.3). The 
digestion was performed in PBS buffer for more than four hours in the cold room. Untagged 
Pol II CTD cysteine mutants interact with the Mediator complex for high quality crosslinking. 
 
    1      2     3     4       5 
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Figure 3.3 Thrombin digestion of GST-CTD cysteine mutants. Lane 1: Precision plus 
protein dual color standards (Bio-Rad); lanes 2: GST-CTDr31C; lanes 3: GST-CTDr38C; 
lanes 4: GST-CTDr52C; lanes 5: Thrombin digestion of GST-CTDr31C; lanes 6: Thrombin 
digestion of GST-CTDr38C; lanes 7: Thrombin digestion of GST-CTDr52C; lanes 8: 
CTDr31C; lanes 9: CTDr38C; lanes 10: CTDr52C. 
 
3.1.4 Determination of the Mediator complex interacting with the first half or the second 
half of the Pol II CTD 
           Both the core and T/G-Mediator was confirmed to bind the first half and the second 
half of the Pol II CTD by GST pull-down assay. 
           Numerous data have shown that Pol II CTD full length strongly binds the Mediator 
complex. To investigate the Pol II CTD-Mediator interaction mechanism, it is good to know 
whether there is any difference between them because the second half of the Pol II CTD is 
more divergent than the first half. I did the in vitro binding assays between the Mediator 
complex and the first half or the second half of the Pol II CTD. Preliminary results showed 
that both the first half (repeats 1-24) and the second half (repeats 25-52) of the Pol II CTD can 
bind P0.5M containing larger Mediator complexes (Figure 3.4), and also to Q1M containing 
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the core Mediator complexes (Figure 3.5), like Pol II CTD full length. This result implies that 
there are multiple Pol II CTD-Mediator interaction sites or this interaction may be quite 
flexible.  
 
 
Figure 3.4 P0.5M interacting with the first half or the second half of the Pol II CTD. 
Lane1: Precision plus protein dual color standards (Bio-Rad); lanes 2: P0.5M interacting with 
the first half of the Pol II CTD; lane 3: P0.5M interacting with the second half of the Pol II 
CTD. 
 
 
Figure 3.5 Q1M interacting with the first half or the second half of the Pol II CTD. 
Lane1: Precision plus protein dual color standards (Bio-Rad); lanes 2: Q1M interacting with 
the first half of the Pol II CTD; lane 3: Q1M interacting with the second half of the Pol II 
CTD. 
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3.1.5 Identification of Pol II CTD-interacting Mediator subunits by chemical 
crosslinking 
           Med1 and Med23 were uncovered to be the Pol II CTD-interacting Mediator subunits 
using four different Pol II CTD cysteine mutants by chemical crosslinking and western blot . 
           One of critical steps in transcription is the RNA Pol II CTD-Mediator interaction. Here, 
the Mts-Atf-Biotin label transfer reagent was employed to capture RNA Pol II CTD-
interacting Mediator subunits. First, two RNA Pol II CTD cysteine mutants GST-CTDr24C 
and GST-CTDr52C were labeled by the crosslinking reagent. After Thrombin digestion, 
NeutrAvidin beads were used to bind untagged Biotin-labeled Pol II CTD cysteine mutants, 
and then interacted with P1M containing the core Mediator complex. Following photo-
activation, the Pol II CTD-interacting subunits were released from the bait protein and the 
Mediator complex by DTT and urea treatments. The crosslinking product was examined by 
silver stain (Figure 3.6) and Western blots.  
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Figure 3.6 Silver-stained gel for the chemical crosslinking using CTDr24C and 
CTDr52C. Lane1: Precision plus protein dual color standards (Bio-Rad); lane 2: GST-
CTDr24C; lane 3:  labeled GST-CTDr24C; lane 4: labeled CTDr24C; lane 5: final 
crosslinking product after the CTDr24C-P1M interaction; lane 6: GST-CTDr52C; lane 7:  
labeled GST-CTDr52C; lane 8: labeled CTDr52C; lane 9: final crosslinking product after the 
CTDr52C-P1M interaction. 
 
In the chemical crosslinking, the Biotin label can transfer to the interacting Mediator subunit. 
Therefore, Streptavidin-HRP was used to detect Biotin-labeled products with high affinity and 
sensitivity (Figure 3.7). Based on Streptavidin-HRP detection, the result was further examined 
by western blots using the antibody against the Mediator subunit Med9 or Med23 (Figure 3.8). 
 
 
 
 
 
         1    2   3    4    5       6   7    8   9      
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Figure 3.7 Streptavidin-HRP detection for the chemical crosslinking using CTDr24C 
and CTDr52C. Lane1: Precision plus protein dual color standards (Bio-Rad); lane 2: labeled 
GST-CTDr24C; lane 3:  labeled CTDr24C; lane 4: final crosslinking product after the 
CTDr24C-P1M interaction; lane 5: labeled GST-CTDr52C; lane 6: labeled CTDr52C; lane 7: 
final crosslinking product after the CTDr52C-P1M interaction. 
 
 
Figure 3.8 Immunoblots with the antibody against Med9 or Med23 for the chemical 
crosslinking using CTDr24C and CTDr52C. Lane 1: final crosslinking product after the 
CTDr24C-P1M interaction (Anti-Med9); lane 2: final crosslinking product after the 
CTDr52C-P1M interaction (Anti-Med9); lane3: Precision plus protein dual color standards 
(Bio-Rad); lane 4: final crosslinking product after the CTDr24C-P1M interaction (Anti-
Med23); lane 5: final crosslinking product after the CTDr52C-P1M interaction (Anti-Med23). 
 
     1     2      3      4      5      6       7   
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The resulting amount of the crosslinking product is around silver staining detection limit and 
is hard to visualize. However, Streptavidin-HRP detection showed there are several specific 
bands ranging from 60 kD to 150 kD. Combined with the profile of the Mediator complex, 
two antibodies against Med9 and Med23 were used to examine these specific bands. The 
immunoblot results showed there’s nothing for Med9 and there might have the ambiguous 
signal for Med23. Based on western blots, the crosslinking result using CTDr52C was more 
specific and better than the result using CTDr24C. Very likely the cysteine mutant position in 
the repeats affects the chemical crosslinking. I did the crosslinking experiment again using the 
other two cysteine mutants CTDr31C and CTDr38C as well as CTDr52C. I did the same 
crosslinking procedure as indicated above for CTDr31C, CTDr38C, and CTDr52C. Then the 
results were first detected by Streptavidin-HRP (Figure 3.9).  
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Figure 3.9 Streptavidin-HRP detection for the chemical crosslinking using CTDr31C, 
CTDr38C and CTDr52C. Lane1: Precision plus protein dual color standards (Bio-Rad); lane 
2: labeled CTDr31C; lane 3: labeled CTDr38C; lane 4: labeled CTDr52C; lane 5: final 
crosslinking product after the CTDr31C-P1M interaction; lane 6: final crosslinking product 
after the CTDr38C-P1M interaction; lane 7: final crosslinking product after the CTDr52C-
P1M interaction. 
 
The data shown in figure 3.9 indicated there were clearly several particular bands. Next, 
according to the Mediator subunit composition, three antibodies against Med1, Med23, and 
Med26 were specifically selected to identify these potential interacting subunits (Figures 3.10, 
3.11, and 3.12).  
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Figure 3.10 Immunoblots with the antibody against Med1 for the chemical crosslinking 
using CTDr31C, CTDr38C and CTDr52C. Lane 1: labeled GST-CTDr31C; lane 2: labeled 
CTDr31C; lane 3: final crosslinking product after the CTDr31C-P1M interaction; lane 4: 
labeled GST-CTDr38C; lane 5: labeled CTDr38C; lane 6: Final crosslinking product after the 
CTDr38C-P1M interaction; lane 7: labeled GST-CTDr52C; lane 8: labeled CTDr52C; lane 9: 
final crosslinking product after the CTDr52C-P1M interaction; lane 10: P1M. 
 
 
 
Figure 3.11 Immunoblots with the antibody against Med23 for the chemical crosslinking 
using CTDr31C, CTDr38C and CTDr52C. Lane 1: labeled GST-CTDr31C; lane 2: labeled 
CTDr31C; lane 3: final crosslinking product after the CTDr31C-P1M interaction; lane 4: 
labeled GST-CTDr38C; lane 5: labeled CTDr38C; lane 6: final crosslinking product after the 
CTDr38C-P1M interaction; lane 7: labeled GST-CTDr52C; lane 8: labeled CTDr52C; lane 9: 
final crosslinking product after the CTDr52C-P1M interaction; lane 10: P1M. 
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Figure 3.12 Immunoblots with the antibody against Med26 for the chemical crosslinking 
using CTDr31C, CTDr38C and CTDr52C. Lane 1: labeled GST-CTDr31C; lane 2: labeled 
CTDr31C; lane 3: final crosslinking product after the CTDr31C-P1M interaction; lane 4: 
labeled GST-CTDr38C; lane 5: labeled CTDr38C; lane 6: final crosslinking product after the 
CTDr38C-P1M interaction; lane 7: labeled GST-CTDr52C; lane 8: labeled CTDr52C; lane 9: 
final crosslinking product after the CTDr52C-P1M interaction; lane 10: P1M. 
 
           Western blot results revealed that both Med1 and Med23 might be RNA Pol II CTD-
interacting Mediator subunits, but Med26 was not. Three different Pol II CTD cysteine 
mutants had the same results, which further proved that this interaction may have multiple 
binding sites. Absolutely, more experiments are needed for verifying the interacting subunits, 
such as using mass spectrometry to identify the crosslinking products, generating recombinant 
proteins for in vitro binding assays, and using different chemical crosslinking reagents. 
 
3.2 Examining enzymatic activities of Mediator 
           Based on protein sequence analysis, subunits of the core Mediator possess no predicted 
functional motifs. However, it is hard to believe it because Mediator is a large 1.2 MDa multi-
protein complex and different Mediator complexes play distinct roles in vivo and in vitro. 
Another reason is that the assembly of the large Mediator complex is dynamic in cells. The 
Mediator complex may catalyze enzymatic activities for specific regulation in the biological 
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pathway. Recently, some interesting findings have indicated that the Mediator complex has 
enzymatic activities, such as kinase and acetyltransferase activities, and some Mediator 
subunits are assembled in the enzyme complex, such as Med8 involved in the ubiquitin ligase 
(Brower, et al., 2002; Knuesel, et al., 2009; Meyer, et al., 2008). Exploring enzymatic 
activities of Mediator will provide new insight into how Mediator regulates transcription in 
cells. 
 
3.2.1 Isolation of different Mediator complexes 
           Both core Mediator and T/G-Mediator were successfully isolated from HeLa cells, and 
then confirmed by silver stain and Western blot.  
           A good purification for endogenous Mediator is necessary for studying the structure 
and function of the Mediator complex, because Mediator is a large multi-protein complex and 
it’s almost impossible to assemble in vitro. The Taatjes lab has well-established purification 
procedures for different Mediator complexes, such as CDK8-Mediator, the core Mediator and 
T/G-Mediator. A detailed purification procedure was outlined in the figure 2.2. A typical 
preparation begins with nuclei isolated from 100 liters of HeLa cells. For the affinity 
purification step, the activator SREBP was used to pull-down the Mediator complex (Figure 
3.13). Then GSH elutes were run on a linear 15%-40% glycerol gradient. Glycerol gradient 
fractions containing Mediator were aliquoted and stored at -80 °C. The T/G-Mediator 
fractions were purified from P0.5M fraction (Figure 3.14), and the core Mediator fractions 
were from the P1M fraction (Figure 3.15).  
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Figure 3.13 Purified GST-SREBP by GST affinity chromatography . Lane 1: Precision 
plus protein dual color standards (Bio-Rad); lanes 2 and 3: BSA; lanes 4 and 5: GST-SREBP.  
 
 
 
Figure 3.14 Glycerol gradient fractions for T/G-Mediator. Lane M: Precision plus protein 
dual color standards (Bio-Rad); other lanes show glycerol gradient fractions (Fraction number 
is indicated at the top of each gel lane). 
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Figure 3.15 Glycerol gradient fractions for the core Mediator. Lane M: Precision plus 
protein dual color standards (Bio-Rad); other lanes show glycerol gradient fractions (Fraction 
number is indicated at the top of each gel lane). 
 
According to the silver stained gels together with the Mediator subunit composition, the best 
glycerol gradient parts for both the core and T/G-Mediator complexes are fractions 13, 14 and 
15. I used these fractions to test enzymatic activities of Mediator. 
 
3.2.2 RNA Pol II CTD phosphorylation by Mediator 
           In vitro kinase assays revealed that both the core and T/G-Mediator can phosphorylate 
the first half, the second half and full length of the RNA Pol II CTD. Moreover, there was no 
significant difference between the first half and the second half. 
           It is known that RNA Pol II CTD phosphorylation plays central roles in transcription 
and other nuclear events, and different sets of factors recognize specific phosphorylation 
patterns for distinct biological functions (Hirose and Ohkuma, 2007; Meinhart et al., 2005; 
Phatnani and Greenleaf, 2006) such as transcription initiation, splicing, mRNA cleavage 
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and RNA degradation. To date, several cyclin-dependent kinases have been discovered that 
phosphorylate the Pol II CTD, such as CDK7, CDK8 and CDK9. Surprisingly, in mammalian 
cells, the CDK/cyclin pairs alone cannot phosphorylate the targets, which suggests that other 
subunit(s) associated with the CDK/cyclin pair regulate activities of cyclin dependent 
kinases. I tested the core and T/G-Mediator’s kinase activity on different CTD templates. We 
want to know whether there are any phosphorylation difference between the CTD full length 
and the CTD deletion mutants by the core and T/G-Mediator complexes. TFIIH contains the 
CDK7/cyclin H pair and can phosphorylate the Pol II CTD. Here, I examined the core 
Mediator’s kinase activity together with TFIIH on different CTD templates, the full length, 
the first half and second half of the Pol II CTD (Figure 3.16). Then T/G-Mediator was tested 
using the same procedure and same templates indicated above (Figure 3.17). 
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Figure 3.16 Pol II CTD phosphorylation by the core Mediator and TFIIH. Lane 1: the 
CTD full length together with the core Mediator; lane 2: TFIIH together with the core 
Mediator; lanes 3, 9 and 15: the CTD(1-24) together with TFIIH for 0.5, 2 and 8 minutes 
reaction time, respectively; lanes 4, 10 and 16: the CTD(1-24) together with TFIIH and the 
core Mediator for 0.5, 2 and 8 minutes reaction time, respectively; lanes 5, 11 and 17: the 
CTD(25-52) together with TFIIH for 0.5, 2 and 8 minutes reaction time, respectively; lanes 6, 
12 and 18: the CTD(25-52) together with TFIIH and the core Mediator for 0.5, 2 and 8 
minutes reaction time, respectively; lanes 7, 13 and 19: the CTD full length together with 
TFIIH for 0.5, 2 and 8 minutes reaction time, respectively; lanes 8, 14 and 20: the CTD full 
length together with TFIIH and the core Mediator for 0.5, 2 and 8 minutes reaction time, 
respectively. 
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Figure 3.17 Pol II CTD phosphorylation by T/G-Mediator. Lane 1: the CTD full length; 
lane 2: T/G-Mediator; lanes 3, 6, 9 and 12: the CTD(1-24) together with T/G-Mediator for 5, 
10, 30 and 60 minutes reaction time, respectively; lanes 4, 7, 10 and 13: the CTD(25-52) 
together with T/G-Mediator for 5, 10, 30 and 60 minutes reaction time, respectively; lanes 5, 
8, 11 and 14: the CTD full length together with T/G-Mediator for 5, 10, 30 and 60 minutes 
reaction time, respectively. 
 
The results revealed that both the core and T/G-Mediator can phosphorylate the Pol II CTD, 
and there were no significant difference between the first half and the second half of the CTD 
repeats. Perhaps the kinases mainly catalyze the position of amino acid residues in the repeat, 
not in specific repeats. Or there might be the different result in cells because of the 
complicated environment.  Subsequent to these studies it was determined that core Mediator 
examined in Figure 3.16 contained a small amount of co-purifying TFIIH.  This was 
attributed to the phosphorylation observed for “core Mediator.” 
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3.2.3 Histone H3 methylation by T/G-Mediator 
           T/G-Mediator can methylate histone H3, but not  H2A, H2B and H4.  In vitro 
methyltransferase assays also showed that methylation occurred mainly in the amino-terminal 
tail of histone H3.  
           Histone proteins have a wide variety of post-translational modifications, such as 
acetylation, methylation,  phosphorylation, and ubiquitination. Histone modifications can alter 
the electrostatic charge of the protein and result in the structural change, which may affect 
DNA binding or the protein module recognized by a specific factor. Histone methylation is 
one of several key modifications implicated in transcriptional regulation. Both Mediator and 
histone proteins are essential and closely related in transcription.  
           Some evidence indicated that the Mediator complex can phosphorylate and acetylate 
Histone proteins. Here, I examined whether the Mediator complex possesses additional 
enzymatic activities for Histone proteins. First of all, endogenous core histones were used for 
in vitro methyltransferase assays by T/G-Mediator (Figure 3.18). The Coomassie blue-stained 
gel in the left of the figure was used to check the equal loading of substrate amount. 
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Figure 3.18 Methylation of endogenous core histone by T/G-Mediator. Lane 1: Precision 
plus protein dual color standards (Bio-Rad); lane2: endogenous core histone together with 
G9a (positive control); lanes 3: T/G-Mediator; lane 4: endogenous core histone; lanes 5, 6 and 
7: endogenous core histone together with 7.5 µl, 5 µl and 11 µl of T/G-Mediator, respectively.  
 
The data in figure 3.18 clearly showed that T/G-Mediator can methylate H3 of the 
endogenous core histones based upon the fact that there was the band at the same position for 
the positive control (G9a) and nothing for two negative controls. The histone modifications 
mainly occur within the amino-terminal tails. Therefore GST tagged H3(1-37) was next tested 
as the methylation target (Figure 3.19). 
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Figure 3.19 Methylation of GST-H3(1-37) by T/G-Mediator. Lane 1: Precision plus 
protein dual color standards (Bio-Rad); lane2: GST-H3(1-37) together with G9a; lanes 3 and 
4: GST-H3(1-37) together with 2 µl and 8 µl T/G-Mediator, respectively; lanes 5 and 6: 
different amount of GST together with T/G-Mediator. 
 
T/G-Mediator can methylate H3(1-37), although there is some background signal for GST 
alone. In addition, substantial data have revealed there is cross-talk between histone 
modifications, and one modification can be induced or strengthened by other modifications. 
T/G-Mediator can phosphorylate and acetylate histone H3, therefore, I specifically examined 
GST-H3(1-37)’s methylation with the addition of ATP and Acetyl-CoA in the assay (Figure 
3.20).  The result showed there was no difference for the addition of ATP and Acetyl-CoA. 
Perhaps phosphorylation and acetylation didn’t occur in the methyltransferase buffer, or those 
modifications are not functionally related to the H3(1-37) methylation by T/G-Mediator. To 
obtain the best substrate for mass spectrometry, I compared the methylation between H3(1-37) 
and H3 full length (Figure 3.21). The H3 full length didn’t exhibit stronger signal than H3(1-
37). This makes sense, because the histone modification sites are almost exclusively 
positioned in the amino-terminal tail. 
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Figure 3.20 Methylation of GST-H3(1-37) by T/G-Mediator with the addition of ATP 
and Acetyl-CoA. Lane 1: Precision plus protein dual color standards (Bio-Rad); lane2: GST-
H3(1-37) together with G9a; lane 3: GST-H3(1-37) together with T/G-Mediator; lane 4: GST-
H3(1-37) together with T/G-Mediator and ATP and Acetyl-CoA. 
 
 
 
Figure 3.21 Methylation of GST-H3(1-37) and H3 full length by T/G-Mediator. Lane 1: 
Precision plus protein dual color standards (Bio-Rad); lane2: GST together with T/G-
Mediator; lane 3: GST-H3(1-37) together with T/G-Mediator; lane 4: H3 full length together 
with T/G-Mediator. 
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3.2.4 Determination of ubiquitin ligase activity of T/G-Mediator 
           Some interesting bands were obtained from in vitro ubiquitination assay using T/G-
Mediator when the E1 and E2 existed in the reaction, suggesting that the T/G-Mediator 
complex may include some subunit with ubiquitin ligase activity. 
           Recently, H2A and H2B ubiquitination has been proven to play important roles in 
nuclear events. Some ubiquitin-conjugating enzymes (E2) and ubiquitin ligases (E3) have 
been discovered for histone ubiquitination. Here, I used ubiquitin-E1 and UbcH5a to identify 
whether T/G-Mediator contains relevant ubiquitin ligase activity (Figure 3.22).  Interestingly, 
the western blot using the antibody against ubiquitin showed there might be several specific 
bands for T/G-Mediator, which likely implies that some subunit(s) of the Mediator complex 
possess ubiquitin ligase function. The western blot signal of the specific band increased when 
more T/G-Mediator was added in the reaction, suggesting that the band from the 
ubiquitination assay is tightly related to T/G-Mediator. 
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Figure 3.22 Immunoblots of endogenous core histone ubiquitination by T/G-Mediator. 
Lane 1: Precision plus protein dual color standards (Bio-Rad); lane2: endogenous core histone; 
lane 3: TRF1; lane 4: TRF1 ubiquitination (positive control); lane 5: endogenous core histone 
ubiquitination without T/G-Mediator; lanes 6 and 7: endogenous core histone ubiquitination 
with 4 µl and 8 µl of T/G-Mediator, respectively. 
 
3.3 Discussion and the future work 
           The first work accomplished in this thesis was to design and carry out the crosslinking 
experiment for identifying RNA Pol II CTD-interacting Mediator subunits. The final goal of 
this project will elucidate the molecular mechanism of the Pol II CTD-Mediator interaction, 
and further investigate how both of them function in transcription. First of all, I compared 
CTD binding with the Mediator complex between the first half and the second half of the Pol 
II CTD. There is no significant difference between them, which increases the difficulty of 
studying the interaction mechanism. The Pol II CTD cysteine mutants were successfully used 
for the crosslinking experiment. However, different Pol II CTD cysteine mutants affect the 
experimental result. CTDr31C, CTDr38C and CTDr52C worked well, but CTDr24C did not. 
The result detected by Streptavidin-HRP indicated there were several specific bands. Together 
 1  2 3  4   5  6  7 
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with the Mediator subunit profile, Med1 and Med23 were identified to be the interacting 
subunits by western blot with the antibody against specific Mediator subunits. These data 
suggest that the Pol II CTD-Mediator interaction may be dynamic, and has multiple 
interaction sites. More work is needed for investigating the interaction mechanism, such as 
repeating the same procedure using different crosslinking reagents, using mass spectrometry 
to exactly analyze the crosslinking products, performing in vitro binding assays using 
recombinant deletion mutant proteins, and testing the functional relevance of the interaction. 
           The second work accomplished in the thesis was to examine Mediator’s enzymatic 
activities. Both T/G-Mediator highly purified from HeLa cells and related substrates were 
used for testing. Some Mediator complex was shown to have enzymatic activities, but the 
study about it still remains unclear. Mediator is a large, 26-subunit protein complex that can 
adopt different compositions in cells. It is possible that Mediator may possess enzymatic 
activities to accurately implement its functions. Different activity assays indicated that T/G-
Mediator can almost equally phosphorylate the first half and the second half of the Pol II CTD, 
and that T/G-Mediator can methylate histone H3, and that some subunits of T/G-Mediator 
may possess the ubiquitin ligase activity. The above data suggest that Mediator itself may 
have enzymatic activities for its master regulation in transcription, or that the Mediator 
complex with distinct subunit composition plays important role by interacting with other 
enzyme modules. The next experiment will identify the modification pattern by mass 
spectrometry, and also uncover which Mediator subunit possesses the enzymatic activity. This 
work provides new insight into why Mediator is a master regulator in transcription. 
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